Aysar Amer Hameed

Aysar Amer Hameed

Auto-generated profile, based on publicly available information

Aysar Amer Hameed

Department of Pharmacology, Isra University, Amman, Jordan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2026 in Dental and Medical Problems
Verified
Journal Article
Open access
AHAysar Amer Hameed
Aysar Amer Hameed
TATaghreed Altaei
Taghreed Altaei
RARaad Alani
Raad Alani
Oral mucositis (OM) is an oral complication of chemotherapy with agents such as 5-fluorouracil (5-FU). Silymarin (SM) has been utilized therapeutically as a cytoprotective medication. The aim of the study was to evaluate the efficacy of SM as a mucoprotective agent in the treatment of chemotherapy-induced oral mucositis (CIOM) induced by 5-FU, and to assess calprotectin (CP) and S100A12/EN-RAGE levels as novel biomarkers for the evaluation of mucositis. Fifty Wistar albino rats of both sexes were divided randomly into 5 groups. Three groups were treated with different doses of SM (2 mg/kg, 4 mg/kg, 6 mg/kg) for 10 days. Subsequently, the animals from groups I-III received intraperitoneal injections of 5-FU (60 mg/kg) on days 11-14. The 4th group was treated with dimethyl sulfoxide (DMSO) as a control for 10 days, followed by 2 doses of 5-FU, and the 5th group served as a second control and received 5-FU only. The buccal mucosa of the animals was gently injured with a 0.8-mm orthodontic wire (2×6 strokes) under anesthesia. The efficacy of SM treatment on CP and S100A12/EN-RAGE levels in CIOM was evaluated. Macroscopic and histopathological findings were analyzed, and the correlation coefficients between the studied parameters were calculated. The study demonstrated a significant protective effect of SM in chemotherapy-induced buccal mucositis in a dose-dependent manner. Mucositis ulceration was not observed, in contrast to severe OM lesions noted in the control groups. Analysis using a 95% confidence interval (CI) showed highly significant differences between the groups regarding the levels of CP and S100A12/EN-RAGE, as well as very strong correlations with OM ulcers. Based on the macroscopic and histopathological appearance, the study confirmed the dose-dependent protective efficacy of SM treatment in CIOM. In addition, the findings suggest a novel mucoprotective mechanism of SM mediated through its effects on CP and S100A12/EN-RAGE levels. A very strong positive correlation was found between plasma CP and S100A12/EN-RAGE levels and the presence of OM ulcers, suggesting that these biomarkers may be useful in the clinical assessment of CIOM.